Terms: = Leukemia AND SRSF2, Q01130, 6427, SFRS2 AND Treatment
90 results:
1. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.
Patnaik MM; Tefferi A
Am J Hematol; 2024 Jun; 99(6):1142-1165. PubMed ID: 38450850
[TBL] [Abstract] [Full Text] [Related]
2. Discovery of U2AF1 neoantigens in myeloid neoplasms.
Biernacki MA; Lok J; Black RG; Foster KA; Cummings C; Woodward KB; Monahan T; Oehler VG; Stirewalt DL; Wu D; Rongvaux A; Deeg HJ; Bleakley M
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38164756
[TBL] [Abstract] [Full Text] [Related]
3. Atypical CML: diagnosis and treatment.
Breccia M
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):476-482. PubMed ID: 38066919
[TBL] [Abstract] [Full Text] [Related]
4. Germline
Bochicchio MT; Micucci G; Asioli S; Ghetti M; Simonetti G; Lucchesi A
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003211
[TBL] [Abstract] [Full Text] [Related]
5. Genomic Mutation Profiles of Patients with Acute Myeloid leukemia in Korea: a Single-Center Experience.
Han E; Ryu S; Kim D; Koh EH; Byun JH; Lee DH
Clin Lab; 2023 Nov; 69(11):. PubMed ID: 37948498
[TBL] [Abstract] [Full Text] [Related]
6. Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts.
Valent P; Akin C; Arock M; Gleixner KV; Greinix H; Hermine O; Horny HP; Ivanov D; Orfao A; Rabitsch W; Reiter A; Schulenburg A; Sotlar K; Sperr WR; Ustun C
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894806
[TBL] [Abstract] [Full Text] [Related]
7. Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.
Croucher PJP; Ridinger M; Becker PS; Lin TL; Silberman SL; Wang ES; Zeidan AM
Ann Hematol; 2023 Nov; 102(11):3049-3059. PubMed ID: 37702821
[TBL] [Abstract] [Full Text] [Related]
8. [RNA splicing dysregulation in hematological malignancies].
Yoshida M; Yamauchi H; Sakumoto M; Yoshimi A
Rinsho Ketsueki; 2023; 64(7):646-653. PubMed ID: 37544725
[TBL] [Abstract] [Full Text] [Related]
9. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2023 Sep; 98(9):1465-1487. PubMed ID: 37357958
[TBL] [Abstract] [Full Text] [Related]
10. Clinical and prognostic profile of srsf2 and related spliceosome mutations in patients with acute myeloid leukemia.
Jia W; Guo X; Wei Y; Liu J; Can C; Wang R; Yang X; Ji C; Ma D
Mol Biol Rep; 2023 Aug; 50(8):6601-6610. PubMed ID: 37344641
[TBL] [Abstract] [Full Text] [Related]
11. Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2023 Jul; 98(7):1097-1116. PubMed ID: 37309222
[TBL] [Abstract] [Full Text] [Related]
12. Clinical Characteristics and Diagnosis of Acute Myeloid leukemia with CD56-Blastic Plasmacytoid Dendritic Cell Neoplasm.
Zhang X; Wu Y; Li C; Shen K; Li R
Clin Lab; 2023 Jun; 69(6):. PubMed ID: 37307129
[TBL] [Abstract] [Full Text] [Related]
13. [Clinical Characteristics and Survival Analysis of Patients with Chronic Myelomonocytic leukemia].
Wang JY; Chen JF; Wang SF; Guo QH; Ma YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):476-482. PubMed ID: 37096522
[TBL] [Abstract] [Full Text] [Related]
14. Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis.
Lübke J; Naumann N; Metzgeroth G; Kreil S; Brand T; Horny HP; Sotlar K; Cross NCP; Fabarius A; Valent P; Hofmann WK; Reiter A; Schwaab J
Ann Hematol; 2023 Aug; 102(8):2077-2085. PubMed ID: 37012462
[TBL] [Abstract] [Full Text] [Related]
15. Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease.
Sanber K; Ye K; Tsai HL; Newman M; Webster JA; Gojo I; Ghiaur G; Prince GT; Gondek LP; Smith BD; Levis MJ; DeZern AE; Ambinder AJ; Dalton WB; Jain T
Leuk Lymphoma; 2023 Apr; 64(4):846-855. PubMed ID: 36744656
[TBL] [Abstract] [Full Text] [Related]
16. Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy.
Klement P; Fiedler W; Gabdoulline R; Dallmann LK; Wienecke CP; Schiller J; Kandziora C; Teich K; Heida B; Büttner K; Brandes M; Funke C; Wichmann M; Othman B; Chromik J; Amberg S; Kebenko M; Schlipfenbacher V; Wilke AC; Modemann F; Janning M; Serve H; Bokemeyer C; Theile S; Deppermann U; Kranich AL; Ganser A; Thol F; Heuser M
Ann Hematol; 2023 Feb; 102(2):323-328. PubMed ID: 36576532
[TBL] [Abstract] [Full Text] [Related]
17. Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts.
Bewersdorf JP; Rampal RK
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):218-224. PubMed ID: 36485103
[TBL] [Abstract] [Full Text] [Related]
18. Accelerated and blast phase myeloproliferative neoplasms.
Saliba AN; Gangat N
Best Pract Res Clin Haematol; 2022 Jun; 35(2):101379. PubMed ID: 36333070
[TBL] [Abstract] [Full Text] [Related]
19. Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry.
Kennedy VE; Perkins C; Reiter A; Jawhar M; Lübke J; Kluin-Nelemans HC; Shomali W; Langford C; Abuel J; Hermine O; Niedoszytko M; Gorska A; Mital A; Bonadonna P; Zanotti R; Tanasi I; Mattsson M; Hagglund H; Triggiani M; Yavuz AS; Panse J; Christen D; Heizmann M; Shoumariyeh K; Müller S; Elena C; Malcovati L; Fiorelli N; Wortmann F; Vucinic V; Brockow K; Fokoloros C; Papageorgiou SG; Breynaert C; Bullens D; Doubek M; Ilerhaus A; Angelova-Fischer I; Solomianyi O; Várkonyi J; Sabato V; Rüfer A; Schug TD; Hermans MAW; Fortina AB; Caroppo F; Bumbea H; Gulen T; Hartmann K; Elberink HO; Schwaab J; Arock M; Valent P; Sperr WR; Gotlib J
Blood Adv; 2023 May; 7(9):1713-1724. PubMed ID: 36094848
[TBL] [Abstract] [Full Text] [Related]
20. Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.
Kubasch AS; Giagounidis A; Metzgeroth G; Jonasova A; Herbst R; Diaz JMT; De Renzis B; Götze KS; Huetter-Kroenke ML; Gourin MP; Slama B; Dimicoli-Salazar S; Cony-Makhoul P; Laribi K; Park S; Jersemann K; Schipp D; Metzeler KH; Tiebel O; Sockel K; Gloaguen S; Mies A; Chermat F; Thiede C; Sapena R; Schlenk RF; Fenaux P; Platzbecker U; Adès L
Leukemia; 2022 Oct; 36(10):2519-2527. PubMed ID: 36071100
[TBL] [Abstract] [Full Text] [Related]
[Next]
